| human | Q5 |
| P496 | ORCID iD | 0000-0002-4330-2928 |
| P108 | employer | University of Oxford | Q34433 |
| P735 | given name | Jacqueline | Q391321 |
| Jacqueline | Q391321 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q38008749 | 5q- syndrome |
| Q38468057 | A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG) |
| Q52543603 | A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. |
| Q33579912 | A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome |
| Q112716511 | ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine |
| Q35107545 | Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q |
| Q33987086 | Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. |
| Q38049004 | Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies |
| Q43648608 | Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts |
| Q37781950 | Advances in the 5q- syndrome |
| Q63248811 | Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome |
| Q63248800 | Amplification of mitochondrial DNA in acute myeloid leukaemia |
| Q38397580 | Application of CRISPR/Cas9 genome editing to the study and treatment of disease |
| Q38598463 | Application of genome editing technologies to the study and treatment of hematological disease |
| Q63248794 | BRAC2 gene deletion is rare in chronic lymphocytic leukemia |
| Q38278197 | CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q). |
| Q63248731 | CUX1 in leukemia: dosage matters |
| Q54653249 | Characterization of 6q abnormalities in childhood acute myeloid leukemia and identification of a novel t(6;11)(q24.1;p15.5) resulting in a NUP98-C6orf80 fusion in a case of acute megakaryoblastic leukemia. |
| Q40540557 | Chromosomal deletions in myelodysplasia |
| Q41980718 | Chromosomal localization of murine interleukin-1 alpha and beta genes |
| Q37334716 | Clinical and biological implications of driver mutations in myelodysplastic syndromes |
| Q24629306 | Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms |
| Q37470872 | Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression |
| Q63248822 | Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses |
| Q63248775 | Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome |
| Q30883788 | Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes |
| Q46424995 | Del (9q) AML: clinical and cytological characteristics and prognostic implications |
| Q34433808 | Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia |
| Q38507121 | Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells |
| Q29614238 | Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma |
| Q35603613 | Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells |
| Q50007390 | Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells |
| Q41590597 | Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion |
| Q54318410 | Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. |
| Q41211534 | Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma |
| Q63248747 | Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFβ signalling pathways |
| Q60668455 | Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia |
| Q47666196 | Gene expression and risk of leukemic transformation in myelodysplasia |
| Q54614398 | Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. |
| Q37858877 | Gene expression profiling in MDS and AML: potential and future avenues. |
| Q53980481 | Gene expression profiling in polycythemia vera using cDNA microarray technology. |
| Q36221521 | Gene expression profiling in the myelodysplastic syndromes |
| Q57635516 | Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology |
| Q63248755 | Gene expression profiling of CD34+cells in patients with the 5q− syndrome |
| Q43090535 | Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. |
| Q36816162 | Gene silencing by DNA methylation in haematological malignancies |
| Q63248752 | Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays |
| Q33939071 | Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype |
| Q63248797 | Glutathione S-transferase gene deletions in myelodysplasia |
| Q63248829 | HOMOZYGOUS DELETION OF FMS IN A PATIENT WITH THE 5q— SYNDROME |
| Q36737106 | Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes |
| Q37935217 | Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome |
| Q63248805 | Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion |
| Q51063978 | High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation |
| Q63248736 | High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression |
| Q63248760 | High-mobility group A (HMGA) genes: from solid to liquid tumours? |
| Q35607293 | IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells |
| Q63248832 | IN-SITU ANALYSIS OF CALCITONIN AND CGRP EXPRESSION IN MEDULLARY THYROID CARCINOMA |
| Q63248730 | Identification of Gene Expression–Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes |
| Q33595674 | Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability |
| Q63248767 | Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the α-thalassemia myelodysplasia syndrome (ATMDS) |
| Q98196919 | Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
| Q63248737 | Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome |
| Q36941110 | Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. |
| Q40116687 | Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes |
| Q63248843 | Interleukin-1 Beta Gene Deregulation Associated With Chromosomal Rearrangement: A Candidate Initiating Event for Murine Radiation-Myeloid Leukemogenesis? |
| Q35844148 | Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients |
| Q24564365 | Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion |
| Q34637945 | Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis |
| Q53366253 | Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. |
| Q63248733 | Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome |
| Q38354139 | Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes |
| Q31171330 | Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration |
| Q40135314 | MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma |
| Q34122330 | MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential |
| Q63248740 | MicroRNA expression in chronic lymphocytic leukaemia |
| Q57976149 | MicroRNA expression in lymphocyte development and malignancy |
| Q35061526 | MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival |
| Q63248804 | Molecular Diagnosis of the 5q Deletion in Malignant Myeloid Disorders |
| Q63248808 | Molecular Mapping of Uncharacteristically Small 5q Deletions in Two Patients with the 5q- Syndrome: Delineation of the Critical Region on 5q and Identification of a 5q- Breakpoint |
| Q51618906 | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. |
| Q63248801 | Molecular characterization of the 7q deletion in myeloid disorders |
| Q47981317 | Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome |
| Q63248776 | Mutation analysis of the SPARC gene in the 5q-syndrome |
| Q34388734 | Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics |
| Q44999434 | Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia |
| Q47929356 | Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. |
| Q57817695 | Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo |
| Q57817701 | Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo |
| Q63248818 | Myelodysplastic disorders with hemizygous M-CSF receptor gene loss do not show point mutations of codon 969 within the remaining allele |
| Q52839635 | Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. |
| Q41438073 | N-myc expression in neoplasia of human thyroid C-cells |
| Q63248796 | NPM-ALK gene fusion and Hodgkin's disease |
| Q63248765 | NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q) |
| Q63248769 | Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome |
| Q36887104 | Novel genes mapping to the critical region of the 5q- syndrome. |
| Q44287656 | Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. |
| Q36163066 | Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. |
| Q36000867 | PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome |
| Q63248827 | PRACTICAL CONSIDERATIONS IN THE ANALYSIS OF CHROMOSOMAL DELETION BREAKPOINTS BY PULSED FIELD GEL ELECTROPHORESIS |
| Q34429362 | PRPF8 defects cause missplicing in myeloid malignancies. |
| Q56602508 | Physical mapping of the human |
| Q40628573 | Physical mapping of the human genome by pulsed field gel electrophoresis |
| Q39155501 | Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations |
| Q39402061 | Pulsed field gel electrophoresis on frozen tumour tissue sections |
| Q63248815 | Pulsed field gel electrophoresis on single murine hemopoietic colonies |
| Q63248837 | Radiation-induced chromosome 2 rearrangement and initiation of murine acute myeloid leukemia |
| Q38527837 | Recent Advances in the 5q- Syndrome |
| Q54313514 | Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. |
| Q27851991 | Recurrent SETBP1 mutations in atypical chronic myeloid leukemia |
| Q42588518 | Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase |
| Q63248729 | Reduced translation of GATA1 in Diamond-Blackfan anemia |
| Q89791806 | SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications |
| Q94456654 | SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
| Q43767798 | Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells |
| Q27851675 | Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts |
| Q36220721 | Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations |
| Q40519270 | Structural DNA analysis from a single hair root by standard or pulsed field gel electrophoresis |
| Q63248835 | Structure of the granulocyte macrophage colony-stimulating factor gene in patients with the myelodysplastic syndromes |
| Q34157339 | TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia |
| Q91011066 | TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups |
| Q37218274 | TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients |
| Q37377901 | Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes |
| Q43100101 | Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. |
| Q63248795 | Telomere length in myelodysplastic syndromes |
| Q53408015 | Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. |
| Q53423428 | Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. |
| Q45204109 | The 5q- syndrome |
| Q33491066 | The 5q-syndrome. |
| Q22008802 | The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome |
| Q38341998 | The molecular pathogenesis of the myelodysplastic syndromes |
| Q35505803 | The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome |
| Q38147839 | The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes |
| Q33327379 | The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts |
| Q37224370 | The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts |
| Q22254278 | Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs |
| Q90215311 | U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies |
| Q43443310 | Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia |
| Q46960831 | hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia |
| Q36761526 | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling |
Search more.